His impassioned calls for peace are still relevant in the age of ISIS and Boko Haram.
As its name implies, the ISIS app functions like a digital version of a wallet.
FORBES: How AT&T, T-Mobile And Verizon's Mobile Payment App Will Work
Isis Pharmaceuticals in Carlsbad, Calif. is working to invent a drug for Huntington's chorea.
The UK scientists and crew of the James Cook are deploying the ISIS again right now.
But a Genzyme-Isis tie up to distribute mipomersen makes a great deal of sense.
It will also receive two of Isis' diabetes drug candidates and do initial evaluations in humans.
Symphony investors also get a five-year warrant to purchase 4.25 million shares of Isis stock.
Isis Pharmaceuticals has had more false starts at the big time than just about any biotech.
The medicine, a once-a-week injection from Isis Pharmaceuticals, will finish midstage trials any day.
The big question for Isis and Aegerion is how many of these HoFH patients actually exist.
Isis even inked a marketing partnership with Genzyme, which is now part of Sanofi.
Isis and Lilly now are testing the drug on 600 patients in final-phase trials.
Just don't expect a one-for-one recreation of systems like Google Wallet or Isis.
ENGADGET: LevelUp unveils payment docks that take both NFC and QR codes, leave out the guesswork
Though the app is considered (and called) the ISIS mobile wallet, ISIS will not handle payment transactions.
FORBES: How AT&T, T-Mobile And Verizon's Mobile Payment App Will Work
Isis was initially stuck placing orders that exceeded demand, since the fabric was sold in bulk lots.
To say that the launch of Isis has felt drawn out would be a mild understatement.
Food for thought as Isis prepares to hold an analyst meeting in New York on Nov. 13.
Isis will pocket at least a third of the profits from the product if it is approved.
And Ms. Able reports that Cleo's sister, Treasures Biscay's Sapphire, aka Isis, is due in early June.
Thursday, Isis announced trials that could get mipomersen approved in the rare genetic disease familial hypercholesterolemia (FH).
Forbes.com reported last November that the two companies were in negotiations (see "Genzyme Eyes Isis Drug").
Isis Pharmaceuticals of Carlsbad, California, has launched another new class which it hopes will be equally successful.
One big disadvantage of Isis' drugs is that they collect in the liver, potentially causing side effects.
Satellites give us a broad overview of the ocean floor, ISIS and other robots give us the detail.
At first, Isis will get 30% of these profits, but as worldwide sales increase, so will Isis' take.
In 1999 came another setback, when Novartis halted work on Isis' lung cancer drug, then in early-stage trials.
The payments landscape is evolving with the entry of online channels like PayPal, Google wallet and Isis.
FORBES: Even Factoring In Big Growth Visa Looks Full At $150
There's no guarantee that just because Genzyme is looking at Isis that it will come through with a deal.
But Isis would offer Genzyme a bigger opportunity: a chance to launch a drug into a far broader market.
Isis landed its first deal in 1990, with Ciba-Geigy (now part of Novartis), to develop a lung cancer drug.
应用推荐